Determinants of societal costs in Alzheimer's disease: GERAS study baseline results

被引:62
|
作者
Dodel, Richard [1 ]
Belger, Mark [2 ]
Reed, Catherine [2 ]
Wimo, Anders [3 ]
Jones, Roy W. [4 ]
Happich, Michael [2 ]
Argimon, Josep M. [5 ]
Bruno, Giuseppe [6 ]
Vellas, Bruno [7 ]
Maria Haro, Josep [8 ]
机构
[1] Univ Marburg, Dept Neurol, Marburg, Germany
[2] Eli Lilly & Co Ltd, Lilly Res Ctr, Windlesham, Surrey, England
[3] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Div Neurogeriatr, Stockholm, Sweden
[4] Royal United Hosp, RICE Ctr, RICE Res Inst Care Older People, Bath BA1 3NG, Avon, England
[5] Agencia Qualitat & Avaluacio Sanitaries, Barcelona, Spain
[6] Univ Roma La Sapienza, Dept Neurol Sci, Clin Memoria, I-00185 Rome, Italy
[7] Toulouse Univ Hosp, INSERM 1027, Alzheimers Dis Res & Clin Ctr, Gerontopole, Toulouse, France
[8] Univ Barcelona, CIBERSAM, Barcelona, Spain
关键词
Alzheimer's disease; Cost of illness; Dementia; Health care costs; Factors; PREDICTIVE FACTORS; DEMENTIA; CARE; RESOURCES; ILLNESS; BURDEN; SAMPLE; IMPACT;
D O I
10.1016/j.jalz.2015.02.005
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: To identify the main factors associated with societal costs of Alzheimer's disease (AD) in community-dwelling patients across three European countries. Methods: Baseline cost data from a prospective, observational study were used. Assessments included patients' cognition, activities of daily living (ADLs) and behavioral symptoms, and caregiver burden. Cost calculations (2010) from the societal perspective were based on patient/caregiver resource use. Generalized linear models estimated factors associated with costs. Results: Mean monthly costs per patient differed for France (sic1881), Germany (sic2349), and the UK (sic2016), with informal care costs accounting for 50% to 61%. Independent factors associated with costs across all countries were ADL total score, patient living arrangements, caregiver working status, and caregiver burden (all P < .05). Additional factors were significant for the pooled cohort or individual countries. Conclusions: Several patient and caregiver factors, including factors associated with informal care, should be included when evaluating care options for patients with AD. (C) 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:933 / 945
页数:13
相关论文
共 50 条
  • [41] Resource Use and Societal Costs for Crohn's Disease in Sweden
    Mesterton, Johan
    Jonsson, Linus
    Almer, Sven H. C.
    Befrits, Ragnar
    Friis-Liby, Ingalill
    Lindgren, Stefan
    [J]. INFLAMMATORY BOWEL DISEASES, 2009, 15 (12) : 1882 - 1890
  • [42] THE SOCIETAL BURDEN OF PRODROMAL ALZHEIMER'S DISEASE IN THE UNITED STATES
    Saxena, K.
    Sullivan, J.
    Khandker, R.
    Ward, A. S.
    Black, C.
    Silverstein, A. R.
    van Eijndhoven, E.
    Ambegaonkar, B.
    Neumann, P. J.
    [J]. VALUE IN HEALTH, 2019, 22 : S280 - S280
  • [43] Awareness of disease in Alzheimer's disease: preliminary results of a longitudinal study
    Barroso de Sousa, Maria Fernanda
    Santos, Raquel Luiza
    Arcoverde, Cynthia
    Dourado, Marcia
    Laks, Jerson
    [J]. REVISTA DE PSIQUIATRIA CLINICA, 2011, 38 (02): : 57 - 60
  • [44] Genetic Determinants of Disease Progression in Alzheimer's Disease
    Wang, Xingbin
    Lopez, Oscar L.
    Sweet, Robert A.
    Becker, James T.
    DeKosky, Steven T.
    Barmada, Mahmud M.
    Demirci, F. Yesim
    Kamboh, M. Ilyas
    [J]. JOURNAL OF ALZHEIMERS DISEASE, 2015, 43 (02) : 649 - 655
  • [45] The atorvastatin/donepezil in Alzheimer's disease study (LEADe): Design and baseline characteristics
    Jones, Roy W.
    Kivipelto, Miia
    Feldman, Howard
    Sparks, Larry
    Doody, Rachelle
    Waters, David D.
    Hey-Hadavi, Judith
    Breazna, Andrei
    Schindler, Rachel J.
    Ramos, Harry
    [J]. ALZHEIMERS & DEMENTIA, 2008, 4 (02) : 145 - 153
  • [46] Direct costs of Alzheimer’s disease in Germany
    Peter Kiencke
    Dietmar Daniel
    Christine Grimm
    Reinhard Rychlik
    [J]. The European Journal of Health Economics, 2011, 12 : 533 - 539
  • [47] Direct costs of Alzheimer's disease in Germany
    Kiencke, Peter
    Daniel, Dietmar
    Grimm, Christine
    Rychlik, Reinhard
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2011, 12 (06): : 533 - 539
  • [48] Modeling direct costs in Alzheimer's disease
    Murman, DL
    Indurkhya, A
    Liang, J
    [J]. ANNALS OF NEUROLOGY, 1998, 44 (03) : 518 - 518
  • [49] Alzheimer's Disease Anti-Inflammatory Prevention Trial: Design, methods, and baseline results
    Meinert, Curtis L.
    McCaffrey, Lee D.
    Breitner, John C. S.
    [J]. ALZHEIMERS & DEMENTIA, 2009, 5 (02) : 93 - 104
  • [50] Pathological determinants of dementia in Alzheimer's disease
    Royall, DR
    Mulroy, A
    Polk, MJ
    [J]. ANNALS OF NEUROLOGY, 1999, 46 (03) : 451 - 451